The paper gives a brief introduction to canine oncology, including its comparative aspects as basis for recording tumours in the animal kingdom. In an abbreviated presentation of the Norwegian Canine Cancer Project for the years 1990 – 1998, the data (n=14,401) were divided into age groups, each of two years, into different categories of tumours, and into age and gender. As expected, cutaneous histiocytoma was the dominant tumour type in both sexes during the two first years of life. In the age group 2 – 3.99 years histiocytoma was still the largest group in males, but was surpassed by benign epithelial skin tumours in females. After the age of 4 years, benign epithelial skin tumours constituted the greatest circumscribed group in males, and mammary tumours in females, although the summated other tumours, not explained in this survey, dominated overall in males. Maligancies (cancer) were shown in the same way, by corresponding groups of gender and age. While mastocytoma was the most common tumour and non‐Hodgkin's lymphoma the second most common during the two first years of life in females, the situation was reversed in males. Later, mammary tumours dominated in females, while different tumour types not further specified in this summarized report dominated in males, until the end of the age registration (above 14 years). Number, sex and location of most common tumours are shown in a tabular outline. Comparative aspects between human and dog tumours are considered: mammary and testicular neoplasia seemed more frequent in dogs than in humans in Norway, while intestinal, pulmonary and prostatic malignancies were less common in dogs. In our study, vascular tumours and tumour‐like lesions constituted about 3% of the total data. As benign vascular tumours are incompletely reported to the human Cancer Registry, no dependable comparison may be made, but malignant vascular tumours have been on the rise during the last decades in the Norwegian human population, more so in men then in women. Finally, the article deals briefly with the development of endothelial cells, and the sparse information on causal factors of vascular tumours.
This paper deals with a population‐based material collected during the years 1990 – 1998, and comprises 439 tumours and tumour‐like vascular processes from 420 dogs. Anatomic location, age, breed and gender are reported. A distinction is made between benign neoplasms, tumours of intermediate malignancy, and obvious malignant processes (angiosarcomas). Clinical behaviour, comprising recurrence and metastatic disposition, is included. Subclassification is done according to criteria used in human oncology. More than one half (242 of 439) occurred in the skin, and a great majority of skin processes (223 of 242) represented benign tumours or tumour‐like lesions. The next most common site of summarised lesions was the spleen, with 110 cases, with only 17 processes in this organ being defined as benign. Splenic involvement was followed by the liver, with 13 out of 17 processes being angiosarcomas. Eleven of 12 heart tumours were angiosarcomas. A majority of skin haemangiomas was of the cavernous type (108 of 211), and more than one half (10 of 14) of the capillary haemangiomas were located on dorsal sites of the extremities. The mixed capillary/cavernous haemangiomas had a more diffuse distribution, although 20 of 31 were found in the skin of the hind limbs. Only one lymphangioma and one case of angiomatosis were observed. Most tumour‐like proliferations were papillary endothelial hyperplasias. Recurrence occurred in 17 dogs, some of which had received a primary benign diagnosis. Primary metastases were observed in 63 animals, the majority in the spleen and heart. Dissemination involved a further 23 cases (22 had angiosarcoma). The male/female rate of benign tumours was 0.78, for tumour‐like processes 1.83, intermediate malignant tumours 1.65, and angiosarcomas 1.60. With few exceptions, there was an overweight of all subclassified vascular lesions in animals more than 6 years of age.
A light microscopic evaluation of 221 canine vascular tumours and tumour‐like lesions, supplemented by immunohistochemistry (von Willebrand Factor, CD31, vimentin), revealed a high degree of conformity with similar conditions in humans. Four main categories of tumours are reported, i.e. benign types: haemangiomas (n=127) and lymphangioma (n=1); tumour‐like lesions: papillary endothelial hyperplasia (n=8) and vascular ectasias (n=2); neoplasms of intermediate malignancy: haemangioendotheliomas (n=27), and the obvious malignant form: angiosarcomas (n=57). Further classification showed that all subtypes had their human counterparts. Papillary endothelial hyperplasia and arteriovenous and venous haemangiomas are described for the first time in dogs. The combination of conventional histopathologic methods and immunohistochemistry was in many cases very useful diagnostically, the latter technique being in some cases indispensable for establishing a definite diagnosis. In general CD31 was the most useful marker for tumours originating from endothelial cells, especially for poorly differentiated haemangiosarcomas.
The bovine serum amyloid A (SAA) and tissue amyloid A (AA) proteins were isolated and characterized. SAA was isolated from acute phase high density lipoprotein (HDL) of a cow suffering from acute mastitis, and was identified by amino acid sequence analysis. No AA-like protein was found in complex with HDL in serum. Amyloid fibrils isolated from a bovine kidney contained a 9 kDa AA protein and a considerable amount of a 14 kDa protein. Amino acid sequence analysis showed that the largest protein probably represents undegraded SAA. This is an interesting observation which confirms previous works indicating that SAA can be incorporated in the amyloid fibrils without a prior degradation to AA. The partial amino acid sequences of bovine SAA and AA were strikingly homologous to the sequences of corresponding proteins in man and other species.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.